C4 Therapeutics (NASDAQ:CCCC) Now Covered by Analysts at Stephens

Stephens initiated coverage on shares of C4 Therapeutics (NASDAQ:CCCC) in a research note published on Monday, MarketBeat.com reports. The firm issued an equal weight rating and a $4.00 price target on the stock.

Separately, BMO Capital Markets reiterated an “outperform” rating and issued a $20.00 price objective on shares of C4 Therapeutics in a research report on Tuesday, August 6th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $10.00.

C4 Therapeutics Stock Down 1.0 %

Shares of NASDAQ:CCCC opened at $4.01 on Monday. The company has a market cap of $283.07 million, a price-to-earnings ratio of -2.36 and a beta of 3.04. C4 Therapeutics has a fifty-two week low of $1.06 and a fifty-two week high of $11.88. The firm’s 50-day simple moving average is $5.72 and its 200-day simple moving average is $5.66.

C4 Therapeutics (NASDAQ:CCCC) last announced its quarterly earnings data on Thursday, October 31st. The company reported ($0.35) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.05. The company had revenue of $15.36 million for the quarter, compared to analyst estimates of $5.95 million. C4 Therapeutics had a negative return on equity of 42.45% and a negative net margin of 313.35%. On average, research analysts forecast that C4 Therapeutics will post -1.48 EPS for the current year.

Hedge Funds Weigh In On C4 Therapeutics

Several hedge funds have recently bought and sold shares of the company. Headlands Technologies LLC acquired a new stake in C4 Therapeutics in the second quarter valued at $45,000. B. Riley Wealth Advisors Inc. purchased a new stake in shares of C4 Therapeutics in the 2nd quarter worth about $51,000. Point72 DIFC Ltd purchased a new stake in shares of C4 Therapeutics in the 3rd quarter worth about $51,000. Cynosure Group LLC acquired a new stake in C4 Therapeutics in the 3rd quarter valued at about $57,000. Finally, Aigen Investment Management LP purchased a new position in C4 Therapeutics during the 3rd quarter valued at about $82,000. 78.81% of the stock is owned by hedge funds and other institutional investors.

C4 Therapeutics Company Profile

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.